Module 1 Flashcards

1
Q

Define core group

A

sub populations with higher rates of partner change that sustain transmission and persistence in the wider population

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Are sex workers a core group?

A

Idea was that there would be a high rate of STIs within the population of sex workers
Have sex with a ‘bridging’ population of their clients, who would then have sex with the general population and disseminate disease
Disproven in the case of HIV as the Praed Street Project actually found a low rate of HIV within the prostitutes they studied, and found they were more likely to use condoms with clients than with regular boyfriends/non-paying partners

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is R0

A

Basic reproductive number: the average number of secondary infections occurring from a single infected individual in a totally susceptible population.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What does R0 have to be for an epidemic to occur?

A

> 1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is R(t)

A

the average number of secondary infections caused by a single individual at any point in time
R(t) = R0 (S/N) where S/N is the proportion of the population susceptible

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the transmission rate

A

= pcSI/N where:
c = the contact rate
I/N = the proportion of population infectious
p = the probability of transmission when an infection individual contacts a susceptible
S = the number of susceptible individuals

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How do the transmission rate and R(t) change over the course of an epidemic?

A

When we start, R(t) = R0, and R(t) is then declining over the course of the infection.
Transmission rate will increase as the proportion of population who are infectious increases and the contact rate increases, but then will decrease as the supply of susceptible individuals is depleted

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is a point/common source outbreak

A

where all cases have been exposed over a short time period and all infections occur within one incubation peak.
This will produce a single peak of cases.
An example would be food poisoning from a wedding buffet.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is a Continuing source outbreak

A

where all cases have been exposed to an ongoing source of infection.
The infections occur randomly when compared to the incubation period.
An example would be Legionella from a contaminated air conditioning unit.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is a propagated source outbreak

A

where the infection can spread from one person to another.
This produces multiple peaks, and infections occur over several incubation periods.
An example would be a measles outbreak at a school.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is a mixed source outbreak

A

where there is both a common point source and secondary spreading from one person to another.
This produces multiple peaks with infections occurring over multiple incubation periods.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Is access to medicines a human right?

A

Yes:
ICCPR - art 6 - right to life
ICESCR art 12:
Health is a fundamental human right indispensable for the exercise of other human rights
Access to health care
UDHR art 3 - Access to health care
International Covenant on Economic, social and cultural rights - art 12 - the prevention, treatment, and control of epidemic, endemic, occupational, and other diseases
ICESCR GC 12 - To provide essential drugs as defined under the WHO Action Programme on Essential Drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the TRIPS agreement

A

came into force in the late 1990s
They provided preferential trading tariffs for members
However, member countries had to sign up to the whole thing - and one condition was intellectual property rights for pharmaceuticals
This was the result of lobbying by the pharmaceutical company - civil society wasn’t lobbying for as long, and healthcare professionals hadn’t really considered the issue
Tightening of patent protection and consequent diminishing production of generics led to a large global series of demonstrations around he prices of and access to medicines
Globalisation of patent rules
20 year patents on pharmaceutical products
As a result, all new drugs will be patented in all key generic producing countries e.g. India, Brazil, Thailand
Whilst the need for affordable newer drugs increases and the price discounts are insufficient

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the industry strategies to provide access to medicines?

A

Tiered pricing
But the discounts aren’t enough and this isn’t as effective as generic competition
No solution to patent barriers for innovation e.g. paediatric formulations
Voluntary licences
Restrictions still limit the full effect of generic competition e.g. export
Rare and often a response to threats of legal action

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

How do India’s pharmaceutical patent laws work?

A

India’s patent law balances IP and public health - patents are not granted for new uses or new forms of existing medicines unless they demonstrate significant increases in efficacy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What do CIPR have to say about TRIPS and IP

A

“All the evidence we have examined suggests that [IP] plays hardly any role at all, except for those diseases where there is a large market in the developed world, for example diabetes or heart disease”

“There is no evidence that the implementation of the TRIPS agreement in developing countries will significantly boost R&D… Insufficient market incentives are the decisive factor”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Are newly patented drugs ‘breakthroughs’?

A

No -
Very little R&D for NTDs - in 1975-2004 only 1.3% of marketed chemicals
Only 5.9% of newly patented drugs in Canada from 1990-2004 met the criteria of being a ‘breakthrough drug’
68% of new products approved in France between 1981 and 2004 brought ‘nothing new’ over previously available preparations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

WHA’s plan - Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property (2009)?

A

Ensure intellectual property rights do not prevent access
Examine feasibility of voluntary patent pools
Exploratory discussions on biomedical R&D treaty
Addressing de-linkage of the costs of R&D and the price of health products
Explore the award of prizes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

How does the patent pool work

A

Negotiates with patent holders for licences to be available in the pool
Manufacturers then seek a license from the pool to produce a generic drug and pay royalties to the patent holder

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

How does MSF’s push pull pool campaign work?

A

for TB:
Finance R&D through grants (push)
Incentivise R&D achievements with milestone prizes (pull)
Share intellectual property to enable collaboration and fair licensing of successful medicines (pooling)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Brazilian study found that visceral leishmaniasis is 6x higher in households without regular refuse collection compared to those with

A

(Costa et al 2005)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

immigrants to Canada - over 36% of participants were susceptible to M, M, or R

A

Greenaway et al 2007

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Give some stats on the state of water provision globally

A

1.1 billion people lack improved water supply - 17% of the global population
2/3rds of these people live in Asia
World’s population is growing which is putting more pressure on water systems
Urban population is growing, meaning pressures are often very localised; however:
Opportunity to put in place traditional engineering solutions and tax city-dwellers
Internationally, in cities you are better off in terms of water and sanitation than you would be in a rural area

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Give some stats about global sanitation provision

A

Mostly doing worse with sanitation than we are with clean water provision, and this is where most of the disease risk is
2.6 billion people lack improved sanitation - 42% of the global population
More than half live in China or India
69% lack access in rural areas, 22% lack access in urban areas
40% of the world’s hospital beds are occupied by people with enteric infections

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Specifications for a sanitation system

A

No contact by humans with waste materials within the system
No access to the waste materials for insects and animals
No offensive odours or insect nuisance
No unacceptable contamination of groundwater that may pollute springs or wells
No unacceptable contamination of surface water
No unacceptable contamination of surface soil
Simple and inexpensive construction, use, and maintenance
Modesty needs and personal cleansing practices of users are catered for

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Things to consider when designing a sanitation system

A

What is the soil like
How many people will use it, distance between dwellings, interval of emptying
Sanitation ladder - not too technological too soon
Is there water regularly available to flush with?
How will they maintain the system?

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Why is drug resistance e.g. in pneumonia a problem

A

Increased difficulty in control of infectious diseases
Reduced effectiveness of treatment -> longer period of infectiousness -> increased risk of transmission
Growth of global trade and travel allows rapid spread to distant countries
Increased healthcare costs
More expensive therapies required when first line treatments no longer work
Longer duration of illness and treatment
Increased mortality
Failure to respond to standard treatment leads to prolonged illness and greater risk of death

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

What can we do about antimicrobial resistance in pneumonia

A

Vaccinate
Local/national/international surveillance projects
Campaigns promoting judicious use of antimicrobials
Start smart and focus (UK)
Get smart (US)
WHO
R&D of novel therapeutics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Why is it feasible to eradicate polio

A

Effective vaccine
No natural non-human reservoir
Coverage of vaccination improving
Political will

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Summarise the OPV

A

Cheaper
Easier to administer
Secondarily immunises household contacts
Mucosal immunity
Lower rate of seroconversion in developing countries - interference by other infections and diarrhoeal disease
Vaccine Associated Paralytic Poliomylitis (rarely) as OPV is similar to the wild type poliovirus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Summarise the IPV

A

Older
Injected
Induces good humoral immunity against paralysis
Much more limited impact on mucosal immunity against infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Challenges to polio eradication?

A

Effectiveness of OPV
Reaching the communities who need the vaccine
Public and political support for vaccination

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Schistosomiasis life cycle

A

Aquatic snail releases cercaria
Enters via unbroken human skin
Circulates to the liver; pairs up, migrates, lays eggs in blood vessels
Egg rotates in capillaries and bursts open via its spine
Escapes to the bladder or the intestine
If the person defecates in water, the eggs will hatch and the larva will find a snail
If it does, it takes over the snail as an intermediate host
And then multiple through the larval stages
A month later, produces a free swimming larva (cercaria)
Whole lifecycle takes over 2 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

How does schisto cause disease?

A

Not all eggs get out of the body - some get washed to the liver, get stuck there, and die. Then the body recognises them, attacks them, and a scar is formed. Eventually the liver gets entirely blocked and fibrotic, and as much as 20-25 years later there is death, usually due to oesophageal varices and haematemesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Why is schisto especially bad for women?

A

Anaemia -> poor birth outcomes

Female genital schistosomiasis: lesions on cervix which increase the HIV/AIDS risk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Why is schistosomiasis so serious/some stats on the burden

A

2nd most prevalent infectious disease behind malaria
200,000 deaths/year in SSA
Affects 74 tropical countries in Africa, Caribbean, South America, East Asia, and the Middle East
62% of the burden occurs in 10 countries in Africa
Worldwide 700 million people at risk
207 million people infected

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

What are the main interventions for schistosomiasis

A

Mass drug administration to school children and others considered at risk
Health education and behaviour change
Snail control
Improve water and sanitation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

Describe chemical snail control

A

Spraying water bodies with molluscicides
Effective on small water bodies
However, unless carried out intensely and in conjunction with MDA, only a short term solution as rapid re-colonisation can occur

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Describe environmental snail control

A

Reduces the numbers, or in some cases wipes out snail populations
Thomas and Tait (1984): altering light, water chemistry, water flow, sediment type, seasonal drying, aquatic and sub-aquatic plants, introducing other snail species and management of irrigation schemes
Unless there is long-term commitment from rural communities, the rapid reintroduction of the species is inevitable

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

Describe biological snail control

A

Introduce pathogens, parasites, predators, competitors, genetic manipulation
Ideas still in early stages and can be complicated to implement
Due to overfishing of mollusc eating fish, some areas of Lake Malawi have seen an increase in schisto cases
Small community owned projects have implemented fishing boundaries to try and re-establish the fish population to reduce schisto

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

Which water/sanitation strategies are important for schistosomiasis

A

77% reduction in severity and intensity of schistosomiasis can be gained with improved water and sanitation facilities - but just because they are introduced, doesn’t mean they will be maintained
Accessible urinals close by river/pond
Safe laundry area near river/pond

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

What is the point of monitoring a schisto programme

A

Assesses impact - has the program been successful
Provides feedback to:
Affected communities to increase ownership and compliance
Donors to show progress towards objectives and justify continued funding
Enable programme adaptation
Generate scientific data on the factors influencing treatment programme success
Assess whether financial resources are being used appropriately
Advocate for future funding and programme support

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

What are some non-PCT schistosomiasis interventions

A

Competitors and predators
Improved drainage
Waterflow
Water level fluctuations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

How can competitors and predators help schisto

A

Brown and DeVries (1985) - fish predators can dramatically alter the population dynamics of a single snail species

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

How does improved drainage affect schisto

A

R Slootweg and R Keyzer - reducing schistosomiasis infection risks through improved drainage
Reconstruction of the depression zone along the village diminished risk of schistosomiasis transmission considerably
However, a potential transmission site with low numbers of snails remains present near the dam at a far distance from the village

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

How does improved waterflow affect schisto

A

Snails are not found where the water flow velocity exceeds 0.3 m/s except when aquatic vegetation provides them with refuge from the current
High water flow velocities are well tolerated in cement-lined canals
Periodically flush canal sections between the check structures
High water velocity not only removes snails by washing them away or leaving them stranded high on the canal banks, it also scours silt deposits

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

How does improved water level fluctuations affect schisto

A

Important in small canals
Periodic removal of aquatic plants from canals also reduces friction to the water flow, which increases conveyance efficiencies in the irrigation system
In Egypt and Sudan, control of aquatic plants in canals has been applied as an effective method of snail control

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

What health education can you do for schisto

A

Inform, motivate, train and encourage communities and their leaders to play a major role in improving their own health
Studies reveal many think it is an STI
In some countries, it is seen as a coming of age when a boy’s urine is red

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

What are the 5 specific objectives of schisto health education

A

Control of transmission through changes in water contact behaviour
Improved environmental sanitation through the control of urinary and faecal contamination of snail habitats
Compliance in chemotherapy
Assistance and cooperation with snail control programs
The promotion of health-promoting behaviour and community motivation to sustain these programs, together with increasing self reliance in health activities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

Give an example of a time that pressures for more water supply led to schistosomiasis

A

The dam in senegal - OMVS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

Why did the OMVS dam get built

A

Increasing populations in resource poor setting and demand of food leads to construction of dams and irrigation schemes
This can cause transmission intensification or the introduction of diseases into previous non-endemic areas, as in Senegal
1970s - governments of Senegal, Mali an dMauritania established the OMVS to develop and use the resources of the Senegal river
Integrated development scheme was designed leading to the construction of two dams and a barrage at Diama
1976 - USAID and OMVS signed an agreement for a multidisciplinary assessment of the environment to see what the impact would be of the project

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

What conclusions did the USAID study of the OMVS dam have

A

S haematobium in the delta was at a very low level
S mansoni did not occur
Highest schisto prevalences were found in the nomadic tribes disseminating the disease throughout the region
Explanations given:
Low density human population of the delta
Little contact of the population with snail infested waters
Possibility that the strain of the snail in the delta is an inefficient intermediate host for the strain of S. haematobium in the Senegal River Basin
Waters are harmful to schistosome larvae (miracidia) because the river water is acidic with a pH of 6 or below

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

What happened after the Senegal dam was completed

A

Completed in 1985 - in 1988 S mansoni was reported in stool examinations 130km from the dam
In 1989, 49% of stool samples were positive
Children were reporting blood in their urine
90% of the Wolof ethnic group were positive for S haematobium and 87% of another 382 sampled
By 1990, 60% were positive
By 1994, there was splenomegaly, and hepatomegaly in 36% of the population

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

Which factors contributed to the advent of schistosomiasis in Senegal after the dam

A

Physical and chemical changes in the water and environment leading to an increase in snail hosts
Stopped sea water reaching areas further up the river
Increase in Biomphalaria prefer and Bulinus globules
Reduced adverse effects of salinity on the parasite
Increase in the irrigated areas
Stability of water levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q

What actions were taken to get rid of schistosomiasis at the senegal dam

A

Treatment with PZY but only 18% of those treated were cured
Rapid reinfection
Presence of immature worms
Low levels of antischistosome immunity
Resistance/tolerance ot PZQ
Larger average biomass of parasite, therefore less likely to work
Further intervention - prawns
Treatment with a double dose of PZQ, spaced 3 weeks apart
6 weeks earlier, released prawns into the water point and they consumed a huge number of snails
The disease did not build up and build back very quickly
AT the 6 month point he average parasite egg burden of 31 eggs at baseline had fallen to less than 1
At 12 months, the difference in egg burden was not as dramatic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
56
Q

Explain the main results of the study of schistosomiasis variation in China

A

The study examined schistosomiasis in hilly and marshland regions, which both have populations of humans, but the marshland has more cattle (kept by the humans) and the hilly regions have a large rodent population
Rodents were by far the most common host for schistosomiasis in the hilly regions, but were very rarely hosts in the marshland regions
Opposite was true of cattle
Additionally, there was a difference in the timing of cercarial release (when schistosomes would be aiming to infect a host)
In the marshland, cercarial release was in the early morning, before the heat of the day, when people would take their cattle to water
In the hilly regions, it was in the evening.
Therefore, it was clear that schistosomiasis was behaving in different ways in the two regions.
They study then examined the phylogenetic tree of schistosomiasis and found that those in the hilly and in the marshland regions formed two distinct families
Overall, the study showed that schistosomes exhibited variability in their genotype and phenotype which maximised their opportunities for infection and transmission in changing environments.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
57
Q

Explain the arguments for PZQ resistance in schistosomiasis

A

Resistance to all veterinary antihelminthics
Can select for PZQ resistance in animal models
Isolation of parasites with reduced sensitivity in Egypt
Parasite evolution over short time periods
Non-random mating amongst schistosomes
Current/recent MDA programmes are highly successful - strong selective pressures
Currently reliant on a single drug
Monitoring is difficult - no (informative or non-informative) molecular markers available, lack of mechanistic knowledge of PZQ action
Could rare resistance conferring alleles be already present in untreated populations?
Are rare resistance-conferring alleles the only parasite strategy involved in apparent ‘PZQ treatment failures’?

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
58
Q

Explain the arguments against PZQ resistance in schistosomiasis

A
No evidence from China
Probably no drug resistance in Senegal
No increase 10 years later in Egypt
Predicted large refugia
Long generation time in human host
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
59
Q

What are the genetic consequences of MDA on schistosomiasis?

A

No molecular markers for PZQ yet
Significant genetic ‘bottleneck’ was produced by MDA on schistosome population genetics
Hence, the ‘effective reservoir’ may be smaller than previously thought
Continued significant reductions in diversity may reduce the schistosomes’ ability to adapt and survive any future novel environmental selective pressures to which they might be exposed
Or, there may be increased success of a small number of potentially resistant alleles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
60
Q

Would treating everyone in the world with PZQ eradicate schistosomiasis?

A

If you treated everyone in the world with PZQ at the same time you wouldn’t eradicate schistosomiasis
Some would be in the other life cycle stages, not in humans, and the juvenile worms are tolerant to PZQ
There would still be a degree of refugia
Schoolchildren get treated because they are infected with the greatest intensity, but this still leaves infections in older people

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
61
Q

How common is onchocerciasis and how has this changed

A

Also known as river blindness
Very common 60 years ago, with about 50% of people over the age of 40 blind in some areas
Today, virtually no blindness due to onchocerciasis but there are still many people infected especially in Western Central Africa and they have to be treated once a year to prevent the blindness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
62
Q

Explain the life cycle of onchocerciasis/how does it cause disease

A

Parasite
Host is the blackfly, which breeds in fast moving water
This is why it’s common next to rivers (river blindness……….)
The adult worm lives in the human body and gives birth to live larvae
These circulate in the skin waiting to be picked up by a biting blackly
They develop in the blackfly, which infects a human when it bites them
The larvae circulate around the skin and cause intense itching
They also circulate across the retina, and if they do this over a period of time they damage the retina and people go blind

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
63
Q

Life cycle of trachoma?

A

Flies carrying the microorganism land on children’s eyes, to feed on discharge
Women who take care of children also get the infection
Flies that breed in human faeces spread the disease to others
Dirty hands or face cloths also spread the disease
Bacterium produces a characteristic roughening of the inner surface of the eyelids
Incubation period is 5-12 days
Patients experience symptoms of conjunctivitis or irritation, like pink eye

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
64
Q

What happens in active trachoma

A

Usually seen in children, especially pre-school
Characterised by white lumps in the under surface of the upper eyelid (conjunctival follicles or lymphoid germinal centres)
Non-specific inflammation and thickening often associated with papillae
Follicles may also appear at the junction of the cornea and the sclera (limbal follicles)
Active trachoma will often be irritating and have a watery discharge
Bacterial secondary infection may occur and cause a purulent discharge

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
65
Q

What is cicatricial trachoma

A

Later structural changes - Includes scarring in the eyelid (tarsal conjunctive) which leads to distortion of the eyelid with buckling of the lid (tarsus) so that the lashes rub on the eye (trichiasis)
These lashes will lead to corneal opacities and scarring and then to blindness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
66
Q

How common is trachoma/what’s the burden

A

Children are the most susceptible to infection, but the blinding and more serious symptoms tend to be in adulthood
Serious public health problem
Affects the poorest populations in 46 endemic countries
146 million active cases, mainly among children and women
Almost 6 million people are blind or visually disabled due to trachoma
WHO estimates an annual productivity loss of $2.9 billion in 1995, adjusted to $3.5 billion in 2003
Not just Africa - also seen in indigenous populations of Australia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
67
Q

How is trachoma transmitted?

A

Person to person via dirty hands and clothing, but also flies
Direct contact with eye, nose, and throat secretions from affected individuals or contact with fomites
Mechanical transmission (flies)
Environmental risk factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
68
Q

What are the risk factors for trachoma?

A
Lack of water
Absence of latrines or toilets
Poverty in general
Flies
Close proximity to cattle
Crowding
And more
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
69
Q

What did the WHO recommend for trachoma?

A

Annual mass treatment for at least 3 years with 80% population coverage target
Based on expert opinion - no data at the time
May eliminate infection in mesoendemic communities, but the same efforts in hyperendemic communities seem to only cause a decline in active trachoma - not a reduction to 0% - even after multiple years of treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
70
Q

What did the PRET surveys in Gambia find?

A

Partnership for the Rapid Elimination of Trachoma - Gambia
Found that 1 round of treatment reduces TF below the elimination threshold, and further rounds were redundant
Would be better to do one high coverage (>90%) round of treatment to reduce prevalence
However, this isn’t always attainable therefore other measures may be taken

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
71
Q

What is SAFE?

A
Trachoma strategy:
Surgery for trichiasis
Antibiotics
Facial cleanliness
Environmental improvement
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
72
Q

What is the role of surgery in trachoma

A

Reduces risk of progressive corneal opacification
Needs training of surgeons and other staff to carry it out - not enough capacity at present
RCT in Gambia found uptake was 45% higher when the surgery was village based and no difference in success of treatment, cost to patient was lower
Uptake is low - lack of knowledge, cost, fear, inaccessibility
Trichiasis recurrence 20% at one year and 62% at three years
New strategies needed due to high rates of reinfection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
73
Q

What is the role of antibiotics in trachoma

A

Lower the relative risk but not much effect on the individual case
Control programs use them because:
Treat individual infections and reduce risk of developing scarring
Limit transmission to others
Mass treatment with topical tetracycline not feasible - twice a day for many weeks
Single dose azithromycin received better and based on studies, safe MDA strategies were developed
Pfizer donated
This is a good method but resources are lost treating those not infected, therefore rapid diagnostic tests being developed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
74
Q

What is the role of facial cleanliness/environmental improvement in trachoma

A

To prevent transmission rather than treat trichiasis or infection
Gambia study - households who put a higher proportion of water towards hygiene had a reduced risk of trachoma
RCT of hygiene promotion narrowly failed by WHO said it was compelling enough to warrant inclusion in the strategy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
75
Q

What can be done about eye seeking flies in trachoma

A

Not included in SAFE as no evidence that investment would have an impact on transmission
Identifies putative vector Musca sorbens
A large RCT which tested fly control, insecticide and provision of household latrines to reduce breeding materials significantly reduced contact between flies and eyes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
76
Q

Does water have a role in trachoma?

A

No studies looking directly at water and trachoma
Several studies show families living further from water are at a greater risk
Trachoma has also been found to disappear where water has become available even in the absence of an antibiotic based programme

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
77
Q

Why has the SAFE strategy for trachoma been successful?

A

Strategy clear and understandable
Measurable progress
Regular meetings between actors to share achievements and ideas
Delivery of services is performed effectively and inexpensively by non-specialists
Success of each part encourages communities to buy into the rest of it
Mass treatment (single dose azithromycin) is effective, feasible, and popular
Azithromycin is well tolerated, relatively free from side effects and has additional benefits - effective against malaria as well as resp and skin infections
No resistance yet
Donated and shipped to endemic countries by Pfizer
Advocacy by NGOs and WHO has led to governmental commitment in some countries
Strong NGO involvement
Intersectoral programmes - improving water supplies and sanitation while providing eye care

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
78
Q

What does guinea worm do

A

parasite that infects humans through water.
The intermediate host is the water flea.
People are infected when they drink unfiltered water from a pond or stream.
Once in the stomach, the larvae come out and grow.
After a year, they are 1m in length and the worm then travels around the body.
When the female worm is ready to give birth, she forms a blister around the foot.
When the worm begins to the protrude from the body the blister becomes painful and burns.
The person will then go to a pond to relieve the sensation, and the larvae will come out to infect water fleas again.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
79
Q

How common is guinea worm?

A

30 years ago, there were approximately 2 million sufferers - in 2014 there are only about 150 cases globally and most are limited to Southern Sudan.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
80
Q

Why can guinea worm be eradicated?

A

only humans can have guinea worm (there is no animal reservoir) and the water fleas can only transmit it to humans by mistake - i.e. if we can get people to stop drinking unfiltered/unclean water then we can stop transmission.
The reductions so far have been made due to water and sanitation improvements, filtering water, health education, and case management so obviously this are effective and just need to be spread into the final few communities with guinea worm.
There are multiple organisations pushing for eradication including the WHO, Bill & Melinda Gates Foundation and the Carter Centre.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
81
Q

Summarise dengue fever

A

Asymptomatic or undifferentiated fever
Virus incubates for 2-7 days then fever
Headache, muscle and joint pain, self limiting, 1 week

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
82
Q

Summarise dengue haemorrhagic fever

A
4 grades (1-4)
Capillary leakage, thrombocytopenia, altered haemostasis, liver damage, bleeding
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
83
Q

Summarise dengue shock syndrome

A

Massive fluid loss (pleural effusion) can result in shock
Ascites
Bleeding
Hepatomegaly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
84
Q

What is the burden of dengue

A

390 million dengue infected individuals per year of which 96 million showed symptoms
2.5 billion (2/5 of the world’s population) are at risk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
85
Q

What are the immune responses to dengue

A

E is a major target of neutralising and protective antibodies
NS1 is a target of protective antibodies
NS1-specific antibodies lead to ADCC and complement mediated cytotoxicity
NS3 is a major target of T cells (CD4 and CD8)
The IFN response is important
Neutralising antibodies are long-lived
Cross-reactive neutralising antibodies decline rapidly after infection
Protection is thought to be life-long for homotypic virus, but last only a few months for heterotypic virus
Serotype-specific and cross-reactive T cells are detected after infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
86
Q

What is the immunopathogenesis in dengue

A

Observations that viral load is higher in DHF than DF and that there is leakage of cytokines/chemokines/mediators and/or damage of endothelial cells in DHF
The hypothesis is that increased viral load leads to antibody dependent enhancement (ADE) and cross-reactive T cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
87
Q

Explain antibody dependent enhancement

A

Shown in monkeys
Sequential infections of different serotypes compared to the primary serotype
Some showed increased (10-fold) viraemia
Animals given dengue immune serum and then when challenged had higher viraemia than those given non-immune serum
Good animal model is lacking
More cytokine production and less degranulation in DHF compared to DF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
88
Q

What is the hypothesis about the leakage/increased vascular permeability in dengue

A

Endothelial cells were readily infected by dengue virus in vitro
However, only viral antigen found on endothelial cells in vivo
Cytokines/chemokines/mediator effect is preferable because patients quickly recover from the disease without any sequel
TNFalpha, lots of interleukins, complement fragments/complexes were al higher in DHF than DF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
89
Q

What are the criteria for a dengue vaccine?

A

Equal protective responses against all 4 serotypes
Need ‘all or nothing’
One strong dose for immediate effect
Boosting needs to ensure that Ab levels do not drop and also that they all decline at equal rates

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
90
Q

What are some of the current vaccine problems in dengue and the vaccine that has failed

A
Sanofi Pasteur’s Chimerivax
Unequally elicit antibody titres against the 4 serotypes
Surrogate marker(s) for the protection efficacy neutralising antibody titres was not god enough
91
Q

What are some non-vaccine dengue control options

A

Vector control:
Control mosquito spread
No stagnant water
Upside down buckets, tyres need to be removed/righted
Careful transport of travellers
‘Vaccinating’ mosquitoes by infecting them with wolbachia bacteria
Global warming needs to be considered as it is leading to mosquito spread

92
Q

Why is rabies important?

A

Viral disease
Causes estimated 55,000 deaths per year in Asia and Africa
Once symptoms develop the death rate is 100%

93
Q

What have been the control successes in rabies?

A

Canine vaccination
Humane management of dogs
Vaccination of people immediately after exposure
Elimination target is 2015 in Latin America and 2020 in China and Japan

94
Q

What is buruli ulcer and how common is it

A

Buruli ulcer is a chronic skin condition caused by Mycobacterium ulcers infection
Endemic in 33 countries, but is most common in Ghana, Gabon, and Australia.
About 5000 cases per year are reported between all these countries, but poor knowledge and reporting may mean that the true prevalence is higher.
Buruli ulcer can be contained, but it isn’t always - some people suffer very greatly and are killed by it.

95
Q

What are some buruli ulcer control strategies

A

Training health workers (which is vital because there are so few cases)
Early case detection and treatment with antibiotics to prevent complications
Generally better case management with surgery if necessary.

96
Q

What is leprosy and what does it do

A

Leprosy is quite unique in that only 1 in 20 people are actually susceptible to it
Caused by a bacterial infection with Mycobacterium leprae
Leads to a chronic disease - the incubation period is very long (about 5 years) and so symptoms take some time to show
Primarily leads to numbnesss and paralysis in the extremities, which can eventually cause permanent disability especially as patients may not notice injuries, which can become infected as a result.
Additionally, it can cause blindness due to damage to the eyelid muscles, which means there is inadequate blinking and the eye itself is damaged.

97
Q

How common is leprosy

A

There were 220,000 cases in 2005, down from 5.2 million in 1985 as a result of political will and commitment towards elimination.
However, the real rates may be higher as patients suffer the stigma of a diagnosis which may discourage them from seeking care.
Due to the disability and the (incorrect) perception of leprosy’s infectiousness, patients can be case out from their communities and suffer a large burden of discrimination leaving them unable to work or marry.

98
Q

What are the strategies to control leprosy

A

Implementing a strategy of early detection and treatment with MDT before the person becomes disabled.
Capacity building will be needed to sustain control
Community education programmes can be used to reduce stigma and discrimination.
Intensified research may provide us new strategies for diagnosis, treatment and control.

99
Q

Is leprosy treatable?

A

There is an effective multi-drug therapy (MDT that has been recommended by the WHO since 1981 to kill the pathogen and cure the patient.
This is now being donated by Novartis.

100
Q

Overview of Chagas disease

A

South American form of sleeping sickness
Trypanosoma cruzi
10 million people infection, can cause major heart problems in up to 30% of these (Cardiomegaly; also megacolon, megaoesophagus)
Transmitted by bed bugs, therefore confined to people with poor quality housing
Recently spread into Europe via immigrants who sell blood

101
Q

Overview of American trypanosomiasis

A

Louisiana and Texas
Treatment costs up to $1000 per year and diagnosis/access to care are major constraints
Vector control is crucial for breaking transmission

102
Q

Overview of trypanosoma brucei gambiense

A

found in West and Central Africa
Represents more than 90% of reported cases of sleeping sickness
Chronic infection
Person can be infected for years without symptoms; when the symptoms do emerge they are often already in an advanced disease stage where the CNS is affected
Transmitted by the Tsetse fly

103
Q

Overview of trypanosoma brucei rhodesiense

A

Represents less than 10% of reported cases
Acute infection
First signs and symptoms after a few months or weeks
Disease develops rapidly and invades the CNS
Transmitted by Tsetse fly (which has a very limited distribution)

104
Q

How can we control sleeping sickness

A

Early diagnosis (less than 10,000 cases diagnosed in 2010)
Therapy to infected persons (drugs donated by Sanofi and Bayer)
Tsetse control
New therapy using systemic insecticides in cattle so that when the fly bites the cattle, it dies

105
Q

What is loa loa

A

a filarial worm distributed around West and Central Africa

Transmitted by Tabanids (horseflies).

106
Q

Why is loa loa important?

A

There is no pathology in loa loa in itself - you will not know that you have it, although some patients can develop lymphoedema.
Important because albendazole and ivermectin (used in the mass treatment of lymphatic filariasis and onchocerciasis) can cause serious side effects in people infected with Loa Loa.
Especially true of people with high Loa Loa microfilarial densities.

107
Q

Why do albendazole and ivermectin cause side effects in people with loa loa?

A

The idea is that killing large numbers of microfilaria, some of which may be near the ocular and brain regions, can lead to encephalopathy.

108
Q

What do we need to control loa loa

A

the development of more specific diagnostic tests for Loa Loa to identify high risk areas prior to mass treatment.

109
Q

What is cysticercosis and how do you get it

A

Cysticercosis is caused by the Taenia solium worm which can be contracted by eating uncooked pork.

110
Q

How does cysticercosis cause disease

A

It is the eggs which are ingested.
The eggs form a cyst in the human host, which tends to be in the brain.
The cyst then causes seizures - it is the cause of 10% of seizures presenting to emergency departments in Los Angeles.
Most common cause of seizures in Hispanic Americans.
41,400-169,000 cases.
The eggs of the worm will then be excreted in the stool (the adult worm lives in the human gut)

111
Q

How should we control cysticercosis

A

Poor hygiene is generally the cause of humans consuming eggs and therefore the cause of epilepsy - so better hygiene is ultimately the best control measure for cysticercosis.
The adult worm in humans is susceptible to praziquantel which also kills the cyst in the brain.
This can change the cyst from asymptomatic to symptomatic, and hence should be considered when treating schistosomiasis.
Pigs can also be treated, but hygiene is still a better intervention.

112
Q

What are the 2 main kinds of leishmaniasis

A

Cutaneous

Visceral

113
Q

Outline cutaneous leishmaniasis

A

Most common form of leishmaniasis affecting humans
Skin infection caused by a single celled parasite, transmitted by phlebotomine sandfly; there are about 20 species of Leishmania that can cause cutaneous leishmaniasis
Nasty, suppurating wound at the site of the bite which heals in about 6 months
Can ulcerate and become secondarily infected
Can become a ‘mucocutaneous’ form causing gross mutilation by destroying soft tissues in the nose, mouth, and throat

114
Q

Outline visceral leishmaniasis

A

Most severe form
Leads to fever, weight loss, and an enlarged spleen and liver
Patients will have a low RBC (anaemia), low WBC, and low platelets
If untreated, very fatal

115
Q

How is leishmaniasis transmitted

A

Transmitted by sandflies, which are small enough to go through a mosquito net and produce a pinprick bite

116
Q

Where does leishmaniasis occur

A

90% of causes of cutaneous leishmaniasis occur in parts of Afghanistan, Algeria, Iran, Iraq, Saudi Arabia, and Syria, and in Brazil and Peru
Over 90% cause of visceral leishmaniasis occur in India, Bangladesh, Nepal, Sudan, and Brazil

117
Q

Control strategies for leishmaniasis

A

Early diagnosis and effective case management
Vector control e.g. insecticide spray, personal protection
Effective disease surveillance
Control of reservoir hosts (dogs and other animals)
Social mobilisation and strengthening partnerships with the community, with effective behavioural change interventions

118
Q

How common is diarrhoeal disease/which diarrhoeal diseases

A

Diarrhoeal disease makes up a large part of infant mortality
Associated mostly with poverty and poor infrastructure.
Cause of 8.8 million deaths of children under the age of 5 in 2008, and a large proportion of mortality in under 5s is due to infectious diseases (68%)
The main globally important diarrhoeal diseases are Shigellosis, viral diarrhoeal diseases (such as rotavirus) and cholera.

119
Q

What is the burden of shigella

A

major cause of dysenteric, or severe, diarrhoea, causing 1.1 million deaths per annum, 61% of which were in those under the age of 5 (Kotloff et all 1999).
Dysenteric diarrhoea responds less well to Oral Rehydration Therapy (ORT) and so the risk of death is about 2-7 times that of just having watery diarrhoea.

120
Q

What is the burden of viral diarrhoeal diseases

A

such as rotavirus are another common cause of diarrhoea worldwide and some are even vaccine preventable.
Rotavirus is the commonest viral gastroenteritis in children and (although also common in the developed world) is a common cause of mortality in the developing world.
About 40% of hospitalisations with diarrhoea in sub-Saharan Africa are due to rotavirus.
Even in the developed world, although rarely fatal it is so common that it can place a significant burden on health systems.

121
Q

What are the trends in burden of diarrhoeal disease

A

trend towards reduction in child mortality due to diarrhoeal disease, most significantly in the countries with the greatest burden, but a large global burden still remains.
This is especially important as tackling diarrhoeal disease will be a vital part of achieving Millennium Development Goal 4 of reducing childhood mortality.

122
Q

What are the risk factors for diarrhoeal disease

A
broad but are mostly associated with poverty and a lack of healthcare provision.  They include: 
Not exclusively breastfeeding
Being underweight
Stunting
Wasting
Vitamin A deficiency
Zinc deficiency
Measles.
123
Q

Why is breastfeeding helpful for diarrhoeal disease prevention

A

Better nutrition
Avoidance of contaminated water
Contains protective factors.
Oligosaccharides may block pathogen attachment to the mucosa
IgA may help to fight off the pathogens, and lactoferrin increases lymphocyte activity, antimicrobial and anti-inflammatory activity.
A systematic review has found that there was a benefit to breastfeeding on mortality from diarrhoeal disease.

124
Q

How can vaccination reduce diarrhoeal disease

A

Measles vaccine
Possible rotavirus vaccine
Cholera vaccine may be available soon

125
Q

there is evidence that a cholera vaccination is now approximately 50% effective against cholera infection - which study

A

(Zaman et al 2010).

126
Q

Evidence about ORS in diarrhoeal disease in children

A

Low osmolality ORS is now recommended, which has been found to produce a 20% reduction in stool output, 30% reduction in vomiting, and a 40% eduction in the need for unscheduled IV treatment (Santosham et al 2010).

127
Q

Why has ORS uptake plateaued and what can we do about this

A

This may be due to less specific funding, or changes to the definition of an acceptable fluid schedule.
In order to increase uptake, ORS could be produced with better flavours (as there is no longer a concern that children might OD since the newer formulations were released), more convenient packaging or dosing, or bundling with zinc, and better distribution, for example through schools or community workers.

128
Q

Evidence for zinc in childhood diarrhoea

A

been found to reduce duration of episodes of both acute and chronic diarrhoea, and the risk of recurrence in the next 2-3 months (Bhutta et al 2013).
When introduced to community programmes, it also increased the uptake of ORS
Overall, Bhutta et al (2013) found a 46% reduction in all cause mortality and a 23% reduction in hospitalisation.
Bundling zinc and ORS may be helpful, as well as task shifting their distribution to community healthcare workers or schools.

129
Q

Evidence for water improvements for diarrhoeal disease

A

Zeng-sui et al (1989) found that deep well tap water provision in rural China significantly reduced rates of some diarrhoeal diseases.
Quick et al studied point of use sterilisation with hypochlorite, durable plastic storage bottles, and community education interventions in Zambia - they found that intervention families had fewer episodes of diarrhoea.

130
Q

What is the Bradley Classification

A

of Water Related Infections can be used to organise water related health problems into four distinct categories: water-washed (or water scarce), water based, water related insect vector, and water borne.

131
Q

What are water washed infections

A

those which undergo person to person transmission due to inadequate personal and domestic hygiene.
This is a water availability, rather than a water quality, issue.
An example would be trachoma, where recurrent chlamydia infections of the eye are caused by inadequate face washing and flies buzzing around the face.
The recurrent conjunctivitis causes scarring of the eyelid and the eyelid starts to turn inwards.
As a result, the lashes scratch the cornea leading to blindness.

132
Q

What are water based infections

A

those where transmission of infections is via an obligatory aquatic host, such as a snail.
An example would be schistosomiasis (bilharzia), a parasitic disease caused by a fluke which has the snail as its host in the water
It causes damage to internal organs, including the liver, and can compare growth and cognitive development in children.
There is a clear relationship between water sanitation and the incidence of schistosomiasis.

133
Q

What are water related insect vector infections

A

those where transmission is by insects which breed in (or bite near) water.
An example would be malaria, a disease caused by Plasmodium species parasites and transmitted by female Anopheles mosquitoes.

134
Q

What are water borne infections

A

those which are contracted when a person drinks or eats contaminated food or water.
An example would be Ascaris and other intestinal infections.
About 1/3 of the world’s population are infected with intestinal worms, mostly children.
These can cause malnutrition, anaemia, malabsorption syndrome, intestinal obstruction, and mental and physical growth retardation or massive dysentery.
Safer water, sanitation, and improved hygiene can reduce the morbidity from Ascaris by 29%.

135
Q

What is the evidence about the burden of poor hand hygiene

A

It is difficult to know the true impact of hand hygiene due to a lack of data in many countries, both outside and inside healthcare facilities.
This could be due to incomplete reporting of cases, or also that in some areas the largest proportion of care is delivered outside a hospital setting.
However, hand hygiene is the most common vehicle to transmit healthcare associated pathogens.
It is definitely capable of transmitting diarrhoeal disease, which represents a large proportion of the burden of disease in developing countries.
Diarrhoeal disease can cause more serious illnesses (or increase the severity of baseline illnesses), prolong stays in healthcare, cause long term disability and excess deaths,a s well as having a high additional financial burden and high personal costs on patients and their families.
In 2011, 2.5 billion people still lacked access to improved sanitation facilities.

136
Q

What is the evidence behind promoting hand hygiene’s impact on diarrhoeal disease

A

promoting hand washing can reduce diarrhoea episodes by about 1/3
This is comparable to the effect of clean water provision in a low-income area, which is arguably more expensive and more difficult to do.
One paper found that using soap for hand washing had more of an impact on diarrhoeal disease than refuse disposal, or the mother’s education.

137
Q

What is the WHO’s package of hand hygiene measures

A

System change - access to safe, continuous water supply as well as to soap and towels, readily accessible alcohol hand rub at the point of care
Training/education - providing regular training to al health care workers
Evaluation and feedback
Reminders in the workplace
Create an institutional safety environment

138
Q

What is the gold standard for monitoring hand hygiene

A

direct observation, and this has been found to be fundamental to confronting health care workers with their actual behaviour and to call for accountability with regard to patient safety (Allegranzi et al 2013) but this is expensive and logistically difficult in resource poor settings.
It also can modify behaviour by itself.

139
Q

What is the burden of hepatitis C

A

Hepatitis C is widespread and there are areas of high infection, for example in Egypt and Italy.
Its consequences are similar to hepatitis B, with patients progressing to liver cirrhosis or liver cancer.
Many people die from Hep C related disease - there are 130-150 million people with chronic hepatitis C infection and 350,000 to 500,000 deaths annually from hepatitis C related liver disease.

140
Q

What are the risks of hepatitis C in pregnancy

A

gestational diabetes and preterm delivery.

However, these are difficult to separate from social and behavioural factors (the reasons the person has hepatitis C).

141
Q

What is the role of MTCT in hepatitis C

A

Compared to hepatitis B, there is not much mother to child transmission.
It is difficult to get true transmission figures as those we have vary enormously, but the figure generally used is 3-5%.
This happens either in utero, or peripartum.
Having said this, it is still important to reduce mother to child transmission as much as possible regardless given the outcomes of chronic hepatitis C infection.

142
Q

What are the risk factors associated with transmission at birth in hepatitis C?

A

prolonged rupture of membranes (over 6 hours), exposure to maternal blood during vaginal delivery (consequent to vaginal and/or perineal lacerations), and invasive monitoring of the foetus with scalp electrodes or intrauterine pressure catheter placement.
Much more research has been done on mother to child transmission of HIV, and the risk factors seem to be the same.

143
Q

What are the interventions to prevent MTCT in hepatitis C?

A

There are interventions which have proved to be successful in HIV, but so far these have not been shown to be of much benefit in Hepatitis C.
They include:
Using Caesarean section as the mode of delivery
Formula feeding (there are very low levels of hepatitis C in breast milk)
It is thought that anti-hepatitis C therapies in pregnancy would help but these will not be prescribed in pregnancy at present.
Clearly, more research will be needed to find interventions that work.

144
Q

What is the goal of hepatitis C management and how is this achieved in the UK

A

‘sustained virological response’, or SVR.
In the UK, this is done using three interventions: pegylated interferon (once weekly subcutaneous, provides immune activation), ribavirin (an oral antiviral), and additional drugs for G1 genotype (boceprevir or telaprevir).

145
Q

What are the issues with hepatitis C treatment

A

many side effects including depression and flu-like symptoms, and the additional drugs for the G1 phase have added side effects.
There is up to a year of therapy so it should be carefully planned around work commitments etc.
Patients should be regularly monitored for side effects including liver biochemistry and blood count.

146
Q

What is the cure rate for hepatitis C

A

Cure rates are 50-60% at best, lower (30-40%) if they have HIV coinfection.
Outcomes appear to be similar in low income countries - a study found that cure rates were actually slightly higher in low income countries but this may not be completely accurate.

147
Q

What is the evidence about the new DAA drugs for hepatitis C

A

The new Direct Acting Antiviral (DAA) drugs for hepatitis C have been shown to produce SVR in over 90% of treated people, and SVR reduces the risks of all cause mortality in hepatitis C As well as specific outcomes including hepatocellular carcinoma, liver transplant, and liver related death.
However, the results have not been consistently seen in all studies and there is always a risk of reinfection.

148
Q

What are the three main barriers to hep C treatment worldwide?

A

costs, cure rates, and complexity.

149
Q

Describe the issues about cost of hepatitis C treatment

A

Costs are an issue everywhere, as pricing is based on what the health system will pay. Therefore, there is variation in the cost depending on the location.
The current estimates for the cost of early access to Sofosbuvir are £35k for 12 weeks.
Drug spending is expected to increase by about 200% between 2015 and 2016, which is far more than for other conditions.
To add to this problem, there are no specific global funding mechanisms for HCV.

150
Q

How are things changing for hepatitis C treatment costs

A

Firstly, Gilead is taking forward the model of reducing costs in line with their HIV programme. Tiered prices are being used, and they have recently signed a contract with generics manufacturers.
The manufacturers are developing capacity to produce, for example, daclatasvir.
Additionally, it is hoped that shortened treatment durations may be an option for the future as these seem to work quite well.

151
Q

Describe the cure rates for hepatitis C treatments

A

At the moment, patients can hope for a 50-60% cure rate at best.
The rate is lower if they have HIV coinfection - about 30-40%.
Newer Direct Acting Antiviral drugs (DAAs) have been reported as inducing SVR in 90% of patients but this has not been consistently shown in all studies.
Further research is needed into the DAAs to see if they will actually provide a higher cure rate of hepatitis C.

152
Q

Why are some hepatitis C patients not treated, other than due to cost?

A

also due to under-diagnosis.
About 80% of HCV cases are undiagnosed, and so there may be some role for screening to ensure all cases are identified, especially amongst the HIV positive population.

153
Q

What are the issues with hepatitis C treatment complexity

A

HCV treatment is highly toxic and can therefore be complicated, as it can cause secondary issues such as anaemia and depression.
There is potential for simplified monitoring tests during treatment, which would hopefully allow us to extend treatment programmes to lower-resource settings where it is currently difficult to monitor the treatment.
Additionally, in the future it is hoped that there will be options for treatment depending on genotype, as the genotypes vary globally.
Treatment could hopefully also be shortened - currently can take a year

154
Q

How can HCV treatment delivery be improved?

A

there can hopefully some improvements made to health systems to allow for task shifting and integration with other services (for example HIV).
Patient and community engagement will be needed to encourage people to come forward for testing.

155
Q

Where are we on an HCV vaccine? Does it matter?

A

An HCV vaccine would probably be the most cost effective and best strategy to control HCV.
However, it is difficult to produce a vaccine as the genotypes vary according to geographical region.
We cannot use an attenuated vaccine as natural immunity is not complete or fully understood, although there is evidence that reinfection is associated with lower viraemia and a shorter duration of viraemia.

156
Q

Outline chikungunya

A

Alphavirus, spread by A. aegypti mosquitoes
Prevalent in the Indian Ocean region - Reunion, Maldives, Sri Lanka, India
Distribution is different from Dengue - focused on South East Asia and less in South America and other places where dengue is prevalent
Emerging mosquito borne virus
Usually causes a short lived illness with high fever, rash,and arthritis especially of the small joints
Some suggestion it could lead to chronic problems
May have the ability to cause a lot of morbidity and mortality

157
Q

Summarise the burden of hepatitis B and C

A

High prevalence globally - both contribute to sustained global morbidity and mortality from chronic liver disease, cirrhosis, and hepatocellular carcinoma
HBV vaccination is widely implemented but for HCV there is no effective vaccine on the horizon
Hepatitis B
350 million chronically infected
More than 1 million deaths per year
Prevalence is high in Africa, especially West Africa
Infection up to 10-15% in some areas
Hepatitis C
130-150 million people with chronic hepatitis C infection
350,000 to 500,000 deaths annually from hepatitis C related liver disease.

158
Q

Outline the barriers to hepatitis B treatment globally

A
Global health agenda
Requirement for complex diagnostics
Drug cost and availability
Skills and education
Lack of political will
Financing issues
159
Q

Explain why hep B should be on the global health agenda

A

Not an NTD even though 2 billion people have been infected and there are 350-400 million with chronic HBV, 25-40% of which will die of cirrhosis or liver cancer
HBV is 50-100 times more common than HIV

160
Q

Why does hep B need complex diagnostics

A

Complex due to the presence of different stages and the need for LFTs as well as hepatitis B tests
Need to decide who should be treated, and the benefits of treatment depend on the severity of liver disease and the probability of treatment response
Hopefully newer drugs will be more effective and with fewer adverse effects so you can just treat more people

161
Q

What tests are currently needed for a hep B treatment decision

A
Haematology
Biochemistry
Viral serology
Viral load testing
Liver biopsy and histology
These require lots of specific equipment and training
162
Q

What improvements are being made to hep B diagnostics

A

guidelines are being adapted for low resource settings and new innovative tools:
Low cost point of care tests
Dried blood spot testing
Non invasive markers of liver fibrosis

163
Q

Describe the issues of drug cost in hep B

A

Costs are high generally
However, drug prices in general have decreased e.g. tenofovir
Generic prices seem to be static
One consequence of this is drug resistance - because lamivudine was cheaper and has been available longer, many people in SSA and SE Asia have been treated with it and are now resistant (there are now different guidelines)

164
Q

Describe the issues, and a possible solution, to lack of skills and education to treat hep B

A
Need local capacity building and training e.g.:
Screening teams
Treatment work up including labs
Monitoring during treatment
Side effects of treatment
Treatment failure
?End points of therapy
HIV uses similar drugs in similar places, so integration with HIV services may have a benefit:
Trained staff
Lab facilities
Drug supply
Management of coinfection
165
Q

Describe the financing situation for hep B and C

A

No specific global funding mechanisms for HCV or HBV
Access to treatment is likely to be limited in European countries
Global Fund is limited to TB, HIV and malaria
UNITAID is hopefully going to help:
Improving market for drugs and diagnostics
Moving into HIV/HCV coinfection
French government are strong advocates of expanded remit
UK government resistance has waned

166
Q

What are the recommendations about hep B vaccination

A

A safe and effective hepatitis B vaccine has been available since 1982
WHO recommends universal infant vaccination since 1992
Reduces risk of chronic HBV infection and HCC
Many examples of successful vaccination programmes worldwide, but not all countries vaccinate

167
Q

Describe the impact of hep B vaccination in the Gambia and Taiwan

A

Gambia has been vaccinating since 1986, RCT randomised half the country to vaccine and half to no vaccine
Found 67% efficacy against infection and 96.6% efficacy against chronic infection at 15 years
Vaccination in Taiwan, since 1984, has been very systematic
Age specific incidence has greatly decreased following vaccination
There were some very young liver cancers in Taiwan, but rates have now decreased

168
Q

What are the main advantages of hep B vaccination?

A

Reduces risk of chronic HBV infection and HCC

Infant vaccination is very cheap and effective

169
Q

Why is hep B infant vaccination not the ‘whole answer’

A

coverage is suboptimal and is most suboptimal in places where the prevalence is high
Secondly, infant vaccination reduces childhood transmission but doesn’t eliminate risk of perinatal transmission
And perinatal transmission has the highest risk of becoming a chronic carrier

170
Q

Why is perinatal hep B transmission important?

A

Most of the ill health effects of hepatitis B are due to chronic infection
25% of people with chronic HBV develop cirrhosis or liver cancer
About 600,000 (up to 1 million) die annually of HBV related disease
The risk of chronic carriage depends on the method of transmission of HBV:
Perinatally - 90%
Childhood - 30-50%
Adult - 5%
Therefore, perinatal transmission is hugely important in causing the morbidity and mortality of HBV
Perinatal transmission accounts for most transmission in SE Asia, whereas childhood transmission is the main route of transmission in SSA
This creates a vicious cycle as you are more likely to chronically carry in the areas where HBV is already very common

171
Q

Outline how we can prevent perinatal HBV transmission

A

Birth dose vaccine
Birth dose immunoglobulin
Treatment of highly infectious mothers

172
Q

What is the role of vaccination in HBV transmission

A

Infant vaccination
Cheap and effective
Reduces incidence and childhood transmission
However doesn’t eliminate risk of perinatal transmission and coverage isn’t great, especially in areas where HBV is high

173
Q

What is the role of IVIG in HBV transmission

A

Passive immunisation with IVIG
Reduces transmission from the mother
However, storage and delivery of IVIG is a problem

174
Q

What is the role of treating mothers in HBV transmission

A

Treat highly infectious mothers
Usually in the 3rd trimester
Reduces transmission
Not routinely practiced:
Need to know if a mother is positive or negative (therefore needing good antenatal care)
Also need facilities to check viral load and e antigen
Then you also need access to treatment

175
Q

Summarise the barriers to reducing perinatal HBV transmission

A

Good antenatal care system
Viral load and HBeAg testing
Logistics and access to rural areas
Finances

176
Q

Why is treating chronic HBV carriers important?

A

The pool of chronic HBV carriers are the ones at risk of developing cirrhosis of HCC
If vaccination coverage is suboptimal, they will also be able to contribute to ongoing transmission

177
Q

What are the 2 main strategies to improve treatment of chronic HBV

A

we may need to consider screening to find those who are chronically infected
Also need to expand access to antiviral therapy in resource poor settings

178
Q

New DAAs:
Minimum costs of treatment and diagnostics to cure HCV were estimated at US$174-354 per person without genotyping, US$264-444 with genotyping
Assumes large scale treatment programmes can be established similar to those for HIV/AIDS
Treatments with proven pan-genotypic activity will be require to avoid expensive pre-treatment genotyping
Other new drugs can be evaluated using the same methods

A

Hill et al 2014:

179
Q

What are the major global sexually transmitted diseases, other than HIV?

A

gonorrhoea, chlamydia, HSV 1/2, HPV and syphilis

180
Q

What is the burden of curable STIs?

A

Whilst these diseases do not contribute much mortality, they do cause a significant burden of disability, particularly in the form of female infertility.
There are only an estimated 0.1 million deaths annually from STIs other than HIV.
However, there were an estimated 5.1 million years old due to disability in women in 2002, and 1.9 million in men.
One of the issues with the global burden of curable STIs is that many of the infections are asymptomatic, and so the true prevalence rates may be much higher than the numbers diagnosed in STI clinics.

181
Q

WHO sexual violence definition

A

“Any sexual act, attempt to obtain a sexual act, unwanted sexual comments of advances, or acts to traffic, or otherwise directed, against a person’s sexuality using coercion, by any person regardless of their relationship to the victim, in any setting, including but not limited to home and work”

182
Q

CDC sexual violence definition

A

“Sexual violence is any sexual act that is perpetrated against someone’s will. SV encompasses a range of offences, including a completed non-consensual sex act (i.e. rape) an attempted non-consensual sex act, abusive sexual contact (i.e. unwanted touching) and non-contact sexual abuse (e.g. threatened sexual violence, exhibitionism, verbal sexual harassment). All types involve victims who do not consent, or who are unable to consent, or refuse to allow the act”

183
Q

Characteristics of sexual violence

A

Type of violence: physical force/psychological violence
Type of act: anal, vaginal, oral
Type of perpetrator: stranger/intimate
Number of perpetrators: one/several (gang rape/streamlining in South Africa)
Frequency
Intensity/severity

184
Q

What are the determinants of sexual violence

A

Men and women can be victims of sexual violence although the vast majority of sexually violent acts are committed by men against women and children
It is a gendered phenomenon: its nature and extent are a reflection of pre existing social, cultural, end economic disparities between men and women
Rape is an act through which men communicate their power to their victim
Sexual violence has been linked to a cluster of male behaviours which include: sexual and physical violence, having many sexual partners, transactional sex, and alcohol abuse
Can be an act of punishment and an expression of holding power over someone, and it can be an act through which the perpetrators affirm to themselves a sense of power which they may not feel in other aspects o their lives
Male privilege and control was identified as one of the three top factors predicting the perpetration of violence against women

185
Q

Outline the strategies to reduce sexual violence

A

Reducing alcohol abuse
Behaviour change communication strategies
Programs targeting gender attitudes and norms
Structural interventions:
Public awareness
Economic empowerment of women
Strengthening laws and policies
Health services:
Access to emergency reproductive health services
Prevention
Health services integration

186
Q

What are the problems with measuring sexual violence

A

High levels of underreporting
Fear of revenge
Fear of stigmatisation
Inefficient and corrupt justice systems
When taking surveys, need to be aware that ‘sex’ can be interpreted in different ways, and some ways of asking questions will obtain more accurate results than others
Direct questions about their experience of specific acts of violence over a defined period of time results in higher disclosure than generic questions about whether the respondent has been ‘abused’ or has experienced ‘domestic violence’, ‘rape’ or ‘sexual abuse’

187
Q

What were the WHO’s findings on the prevalence of sexual violence

A

Global prevalence of physical and/or sexual intimate partner violence among all ever-partnered women was 30%
Global lifetime prevalence of non sexual violence is 7.2%
Indicates that the perpetrators of sexual violence are most often an intimate partner or family member
Globally, 35.6% of women have ever experienced either non-partner sexual violence or physical or sexual violence by an intimate partner, or both
Up to 1/3 of girls report that their first sexual experience was forced
Between 250,000 and 500,000 women were raped in Rwanda during the 1994 genocide
Highest worldwide prevalences were in the Mediterranean region, then South East Asia then West Africa

188
Q

Why might HIV prevalence among young African women be higher than that in young African men?

A

HIV prevalence among young women in SSA is several folds higher than in young men of the same age - could be due to:
Age differentials in mixing patterns (sugar daddies)
Transactional sex
Higher susceptibility of genital tract at a young age
Sexual violence
Young women often have sexual relationships with older men for money, survival, goods e.g. mobile phones

189
Q

What are some of the health consequences of sexual violence

A

PTSD, social exclusion and rejection, pelvic fistulae, and many more - HIV is just one

190
Q

What is the evidence for a link between sexual violence and HIV

A

Of 5 studies on incident HIV and STI, 3 large studies (from SSA and India) found an increased risk of HIV/STI among those reporting partner violence
The 4th study among women attending substance misuse clinics in the USA used self reported data on HIV and STI diagnosis and found some evidence of lower risk of HIV among those reporting intimate partner violence
The best estimate is an odds ratio of 1.52 (CI 1.03-2.23)

191
Q

What are the possible biological mechanisms of sexual violence causing HIV

A

Genito anal injury
Age related anatomic/physiological characteristics
Pregnancy - much more evidence coming out that women who are pregnant have a higher risk of acquiring HIV when exposed to it due to hormonal changes
Heterosexual anal sex
Risk behaviour of the perpetrator (which increases his risk of being infected)

192
Q

What are some risk behaviours that are more likely with sexual violence

A

Have multiple partners
Have sex more often
Practice transactional sex
Practice anal sex
Report symptoms of or have sexually transmitted infections
Also, there is lower condom use due to an inability to negotiate with a violent partner
Proposing the use of the condom may increase women’s risk of violence
There is often more frequent sexual activity as the woman is not able to refuse
It has been proposed that women who have experienced sexual violence may have a weakened immune system but this is not fully understood
Additionally, fear of partner violence and rape impede women’s access to HIV/AIDS information, HIV testing, treatment, and counselling

193
Q

Which groups are particularly vulnerable to sexual violence

A

Widows
Female sex workers
Women in conflict settings
Prisoners

194
Q

What is the global burden of HIV

A

Estimated 34 million people living with HIV
5% adults in sub-Saharan Africa (much higher in some population groups)
0.8% of the global population
Incidence was 2.7 million new cases in 2010
Mortality 1.8 million in 2010
1-1.5 million patients started on ART each year - so more new infections than we are treating
Basically for every person put on treatment 2 are infected
260,000 children die of AIDS every year
30 million AIDS-related deaths to date
Increasing potential treatment costs of $35 billion per year

195
Q

How has HIV treatment changed

A

Simplicity of treatment has improved
Single pill therapy
17% better adherence
Patient preference
Reduced risk of stock outs
More realistic for the developing world
Simpler guidelines also mean no more problems with migration and patients having to switch treatments
More effective therapy with options for those failing treatment
Medication is less toxic and pill burden reduced
Better management of complications
Atripla now costs about £5000-£6000 per year in the UK but can be manufactured and sold for <$99/year in poorer areas

196
Q

History of HIV treatment until the mid 90s

A

First drug was licensed in 1987
Primarily due to repurposing of AZT
Very high doses, so very toxic
Activity of AZT against HIV was shown in 1985, 25 months before licensing
Extended life, but at the cost of high toxicity
Mid-90s - addition of 3rd agents to the earlier combinations of 2 treatments transformed outcomes
The era of Highly Active Anti Retroviral Therapy (HAART) began
Drop in mortality in the UK, which encouraged more people to be tested and treated

197
Q

What are the main control strategies for HIV

A
Primary prevention
Change sexual behaviour, including condom promotion
Clean blood supply
Prevent mother to child transmission
Safe drug use
Vaccines, microbicides, and PrEP
Secondary prevention
Testing and intervention to those infected
Treatment with ARVs
198
Q

Outline condoms as HIV prevention

A

Difficult for women to negotiate condom use with partners due to issues of trust, gender inequality, etc
Also, in areas with high importance fertility, they may not be adopted

199
Q

Outline other STIs’ role in HIV prevention

A

Are associated with the infectiousness of somebody who has HIV - they are more likely to shed the virus in genital secretions
Make someone more susceptible to contracting HIV if exposed - due to breakdown of mucosal surfaces, higher levels of inflammation so more target cells

200
Q

Outline MTCT in HIV prevention

A

Good in the developed world
Methods:
C section birth
Put on ARVs
Don’t breastfeed
In the developing world, ARVs can be made available but C-sections are not so easy to provide
The issues surrounding breastfeeding are also more complicated as there are important benefits to breastfeeding in the developing world; may be more of a risk than from HIV

201
Q

Outline male circumcision in HIV prevention

A

> 57% reduction
Doesn’t prevent transmission from men to women but does reduce men’s susceptibility to infection from when
More complicated with MSM couples
Thought that the surface exposed to the virus is decreased
Also debate about whether the glans epithelium becomes keratinised
Comparative advantage of being a one-time intervention that doesn’t require long-term behaviour change
Meta analysis of data from the one RCT and 6 longitudinal studies showed little evidence that male circumcision directly affects the risk of transmitting HIV to women (Lancet 2009)

202
Q

Outline treatment as prevention in HIV prevention

A

People basically become less infectious with treatment as the viral load is lower
Whenever you encourage people to come forward for testing, starting education programs with availability of ARVs reduces the incidence

203
Q

Are cervical barriers effective in HIV prevention?

A

Not so far

204
Q

Why would sustained injectable ARVs be useful in HIV prevention?

A

Injectable contraception is population in the developing world so the technologies could be rolled out together
Ability to be more spontaneous compared to PrEP or topical microbicides

205
Q

IPREX findings

A

US study
PrEP had an efficacy of about 44%
Up to 92% in those who took the drugs every day

206
Q

CAPRISA findigns

A

topical PrEP (microbicides)
Women applying microbicide 12 hours before and 12 hours after sex
Most effective in the middle of the study - some people stopped using it towards the end
About 54% effective in ‘high adherers’ (>80% adherence)

207
Q

CAPRISA 004 findings

A

Safety and effectiveness of 1% tenofovir gel applied 12 hours before sex, and as soon as possible within 12 hours after sex
Probability of HIV infection was significantly lower in the tenofovir group than the placebo group
Have to bear in mind that a trial reduces incidence in itself just because people are more aware

208
Q

HPTN052 findings

A

Prevention of HIV infection with early antiretroviral therapy
96% reduction in transmission within discordant heterosexual couples when treatment of the infected partner was started earlier rather than based on the standard of a CD4 count of <350 cells/mm3

209
Q

RV144 findings

A

Thai trial
Prime boost vaccine
Protective efficacy a little over 31%
No effect on viral load or CD4 count in subjects infected with HIV
Lessons:
Protection from infection is possible
Low levels of primary neutralising antibody
Limited CD8 T cell immunity
Other immune effectors likely to play a role
Highest protection in first 6-12 months
Antibody titres appear to wane in line with protection
Follow up studies to determine if boosting can prolong protection

210
Q

VOICE findigns

A

Vaginal and Oral Interventions to Control the Epidemic
Multisite PrEP trial in young women in South Africa, Zimbabwe and Uganda
Daily application of 1% tenofovir gel and daily oral tenofovir and tenofovir emtricitabine (Truvada)
No effectiveness
Widespread product non-use (plasma levels taken) despite high end of study retention rates and high self reported product use

211
Q

VOICE-C findings

A

reasons given for non use:
HIV stigma
Fear of being mistakenly labelled as having HIV
Ambivalence about the research process
Confusion about the use of antiretrovirals to prevent infection
The need to balance trial participation with other priorities and social relationships

212
Q

What are the key questions about PrEP?

A

Who will pay for them? Who will be eligible?
IS it safe to give ARV drugs to HIV negative subjects for prolonged periods?
Will people adhere to daily PrEP for prolonged periods (risk perception)
Will PREP change risk behaviour?
Can PrEP be equally effective if used in an intermittent fashion?
If people get infected while taking PrEP, will it impact on subsequent treatment (resistance?)

213
Q

Why is it possible to make an HIV vaccine?

A

Immune control is possible
Majority of HIV infected individuals initially suppress the viral load
Populations resistant to HIV infection exist
Highly exposed, uninfected
Children of infected mothers
Long term non-progressors - control infection for many years
Vaccine candidates in experimental models
Live attenuated SIV
Can’t make a live attenuated HIV but may be able to add HIV to other viruses
Broadly neutralising antibodies
Recent data: CMV vector
First proof of concept in people
RV144 Thai trial: modest level of protection against HIV infection

214
Q

What are the difficulties in making an HIV vaccine?

A

Classic vaccines mimic natural immunity against infection - no one has recovered from HIV infection
Most vaccines protect against disease, not against infection - HIV infection may remain latent for long periods before causing disease (provirus)
Protection against HIV infection may require sterilising immunity y(preventing entry); no current vaccine is known to do this
Many vaccines use attenuated pathogens, this approach would not be appropriate due to safety concerns
HIV has multiple mechanisms of immune evasion
Lack of relevant animal models
Clinical trials are long and costly
A long term effort requires long term, high level global commitment and incentives for industry

215
Q

How does HIV evade the immune system?

A

High levels of mutation
Viral latency and infection of immuno-privileged sites
Absence of neutralising antibodies due to high levels of glycosylation, epitope masking by hypervariable loops, and shedding of monomeric p120
Promotion of Th1 to Th2 switch (misdirection)
Destruction of immune response (CD4 cells role in coordinating immunity)
HIV has relatively few spike glycoproteins on the surface compared to e.g. flu
Only in the right combination for a short time until they break down
Then the internal components are much more immunogenic and not seen on the surface which almost acts like a decoy
Spike envelope is covered in sugar
The sugars are mobile - there is a glycol coat on the envelope
Antibodies don’t like binding to sugar - so we have to try to find ways around the sugar
HIV exists in multiple subtypes (clades) with different geographical distribution
More viral diversity in a single HIV patient than in influenza across the world

216
Q

What is required of an HIV vaccine?

A

Long lived broadly neutralising antibodies
High levels of central and effector memory T cells
Present at the time of exposure
Rapidly boosted by mucosal infection
Augmented by innate responses
Able to rapidly eliminate infection before immune escape

217
Q

What could an HIV vaccine do to block infection?

A

Block HIV from coming into contact with target cells and tissues
Reduce the number of susceptible cells
Control the spread of HIV from infected cells
Eliminate any infected cels that occur within the vaccinated host or enter the host as part of the innoculum

218
Q

Have T cells worked in HIV vaccination?

A

First trials were unsuccessful
Merck Ad5 (vectored vaccine) provided no protection
Draws attention to the potential danger of pre-existing immunity
Magnitude and quality of the bacon induced T cell responses (especially CD8) were not optimal
T cell vaccines are still an important component of the overall vaccine strategy
They provide the critical priming component in combination regimens with env proteins
May substantially impact the magnitude, quality and durability of the antibody response induced by env protein vaccines
Are likely to augment partially protective antibody responses
May control viraemia if breadth and magnitude can be maintained
In non human studies there has been robust control of SIV (simian virus)
They became infected but could eliminate the virus
Don’t understand why the other 50% became infected

219
Q

What have we learned from HIV infection neutralising antibodies (natural)

A

Up to 25% of infected subjects have broadly neutralising antibodies a year or more after infection
1% (elite controllers) have potent activity against a majority of strains
Cross reactive antibodies arise over years - maturation of response (? implications for vaccines)
Maturation likely to focus on less immunogenic, more conserved regions of env
Induction of responses to such regions could provide potent protection

220
Q

What are the major challenges to eliciting broadly neutralising antibodies to HIV?

A
The HIV envelope trimer
Highly variable 
Unstable
Immune evasion
Gp140 mimics ≠ the native structure
221
Q

What are the non-biological challenges in HIV treatment

A
Money
Drug supply chains
Trained staff
Capacity within failing health care systems
Stigma
Gender based violence
Human rights/coercion
Acceptability at a population level
222
Q

What are some remaining challenges in ART treatment globally

A
HR
Decentralisation
Diagnosis
Earlier initiation
Single preferred regimen and improved viral load monitoring
Service integration
223
Q

What are the Causes of late presentation to diagnosis (Study in India, Koran and Allahabad) in HIV?

A
Structural barriers
Livelihood insecurity
Low awareness about services
Weak public health infrastructure
Financial constraints on access
Poor overlap
Social barriers
Gender differences in health seeking behaviour
Problems of disclosure
Stigma about HIV, even amongst staff at treatment centres 
Behavioural barriers
Individual level constraints on behaviour
Neglecting health and symptoms
Fulfilling social expectations
HIV stigma